Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access July 31, 2014

A case of myositis with immunological background associated with statin use

Dragana Protić, Snežana Baltić, Nada Stupar, Slavica Pavlov-Dolijanović, Snežana Mugoša and Zoran Todorović
From the journal Open Medicine


Statins might cause and/or aggravate the immune-mediated myositis in patients on long-term, stable treatment. We provide a case of polymyositis with an immunological background and gastrointestinal and urinary manifestations in patient on long-term, stable atorvastatin treatment for the past six years. The diagnose of polymyositis was established based on clinical symptoms and signs, electromyography and laboratory test results (elevated aspartate aminotransferase 279 U/L, reference range 0–40 U/L; alanine aminotransferase 198 U/L, 0–33 U/L; lactate dehydrogenase 2200 U/L, 103-227 U/L; creatine kinase 7820 U/L, 15–84 U/L; and positive antinuclear antibodies test, titer of 1:160, with suspect antisynthetase antibodies). Polymyositis was probably related to atorvastatin treatment (Naranjo score, 5). Other probable causes of the myositis were rejected. Coricosteroid therapy, methotrexate and supplementation with vitamin D did not improve the condition. The patient remained bedridden and died two months after the hospital discharge due to the acute myocardial infarction.

[1] Hmelin A., Turgeon J., Hydrophilicity/Lipophlicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors, Trends. Pharmacol. Sci., 1998, 19, 26–37 in Google Scholar

[2] Todorovic Z., Nesic Z., Stojanović R., Basta-Jovanović G., Radojevic-Skodrić S., Velicković R., et al., Acute protective effects of simvastatin in the rat model of renal ischemia-reperfusion injury: it is never too late for the pretreatment, J. Pharmacol. Sci., 2008, 107, 465–470 in Google Scholar

[3] Hoffman K.B., Kraus C., Dimbil M., Beatrice A. Golomb B. A., A survey of the FDA’s AERS database regarding muscle and adverse events linked to the statin drug class. (accessed 2013 Jan 31) Search in Google Scholar

[4] Radcliffe K. A., Campbell W. W., Statin myopathy, Curr. Neurol. Neurosci. Rep., 2008, 8, 66–72 in Google Scholar

[5] Marcoff L., Thompson P., The Role of Coenzyme Q10 in Statin-Associated Myopathy, J. Am. Coll. Cardiol., 2007, 49, 2231–2237 in Google Scholar

[6] Sathasivam S., Statin induced myotoxicity, Eur. J. Intern. Med., 2012, 23, 317–324 in Google Scholar

[7] Padala S., Thompson P. D., Statins as a possible cause of inflammatory and necrotizing myopathies, Atherosclerosis., 2012, 222, 15–21 in Google Scholar

[8] Marshall J. B., Kretschmar J. M., Gerhardt D. C., Winship D. H., Winn D., Treadwell E.L., et al., Gastrointestinal manifestations of mixed connective tissue disease, Gastroenterology, 1990, 98, 1232–1238 10.1016/S0016-5085(12)90338-8Search in Google Scholar

[9] Dalakas M. C., Hohlfeld R., Polymyositis and dermatomyositis, Lancet, 2003, 362, 971–982 in Google Scholar

[10] McKenney J. M., Dyslipidemias, atherosclerosis, and coronary heart disease, In: Koda-Kimble M. A (ed.), Applied therapeutics: the clinical use of drugs. 8th ed., Lippencott Williams & Wilkins, 2005 Search in Google Scholar

[11] Hilton-Jones D., Myopathy associated with statin therapy, Neuromuscul. Disord., 2008, 18, 97–98 in Google Scholar PubMed

[12] Naranjo C. A., Busto U., Sellers E. M., Sandor P., Ruiz I., Roberts E. A., et al., A method for estimating the probability of adverse drug reactions, Clin. Pharmacol. Ther., 1981, 30, 239–245 in Google Scholar PubMed

[13] Anonymous. Real world drug outcomes, personalized. (accessed 2013 Jan 15) Search in Google Scholar

[14] Glueck C. J., Abuchaibe C., Wang P., Symptomatic myositis-myalgia in hypercholesterolemic statintreated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle, Med. Hypotheses, 2011, 77, 658–661 in Google Scholar PubMed

[15] Transfeldt E. E., Morley J.E., Segal F., Klein A., Bill P., Fancourt M., Polymyositis as a cause of malabsorption, S. Afr. Med., J 1997, 51, 176–178 Search in Google Scholar

[16] Mansell P. I., Tattersall R. B., Balsitis M., Lowe J., Spiller R.C., Megaduodenum due to hollow visceral myopathy successfully managed by duodenoplasty and feeding jejunostomy, Gut., 1991, 32, 334–337 in Google Scholar PubMed PubMed Central

[17] Hughes A. J., Ferguson I., Rankin E., Kane K., Polymyositis as a cause of total gut failure, Ann. Rheum. Dis., 2002, 61, 305–306 in Google Scholar PubMed PubMed Central

[18] Tzioufas A. G., 2001, Antisynthetase syndrome. (accessed 2013 Feb 08) Search in Google Scholar

[19] Colglazier C. L., Sutej P. G., Laboratory testing in the rheumatic diseases: a practical review, South. Med. J., 2005, 98, 185–191 in Google Scholar PubMed

[20] Mammen A. L., Chung T., Christopher-Stine L., Rosen P., Rosen A., Doering K.R., et al., Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy, Arthritis Rheum., 2011, 63, 713–721 in Google Scholar PubMed PubMed Central

[21] Christopher-Stine L., Casciola-Rosen L. A., Hong G., Chung T., Corse A. M., Mammen A. L., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy, Arthritis Rheum., 2010, 62, 2757–2766 in Google Scholar PubMed PubMed Central

[22] Grable-Esposito P., Katzberg H. D., Greenberg S. A., Srinivasan J., Katz J., Amato A. A., Immunemediated necrotizing myopathy associated with statins, Muscle Nerve, 2010, 41, 185–190 10.1002/mus.21486Search in Google Scholar PubMed

[23] Marie I., Morbidity and mortality in adult polymyositis and dermatomyositis, Curr Rheumatol Rep, 2012, 14, 275–285 in Google Scholar PubMed

[24] Ng M.K., Celermajer D.S., Glucocorticoid treatment and cardiovascular disease, Heart, 2004, 90, 829–830 in Google Scholar PubMed PubMed Central

Published Online: 2014-7-31
Published in Print: 2014-10-1

© 2014 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Scroll Up Arrow